The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline.
Patrick Schoffski
Research Funding - Exelixis
Rossella Elisei
No relevant relationships to disclose
Stefan Müller
No relevant relationships to disclose
Marcia S. Brose
Honoraria - Exelixis
Research Funding - Exelixis
Manisha H. Shah
Research Funding - Bayer; Eisai; Exelixis
Lisa F. Licitra
No relevant relationships to disclose
Barbara Jarzab
Consultant or Advisory Role - AstraZeneca
Expert Testimony - AstraZeneca
Viktor Medvedev
No relevant relationships to disclose
Michael Kreissl
Consultant or Advisory Role - AstraZeneca; Bayer
Honoraria - AstraZeneca; sanofi-synthelabo
Bruno Niederle
No relevant relationships to disclose
Ezra E. W. Cohen
No relevant relationships to disclose
Lori J. Wirth
No relevant relationships to disclose
Haythem Y. Ali
No relevant relationships to disclose
Colin Hessel
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Yifah Yaron
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Douglas Wilmot Ball
Consultant or Advisory Role - Exelixis (U)
Research Funding - Exelixis
Barry Nelkin
Consultant or Advisory Role - Exelixis (U)
Steven I. Sherman
Consultant or Advisory Role - Exelixis
Martin Schlumberger
Consultant or Advisory Role - Exelixis